Ehave Inc Stock Price, News & Analysis

Ehave, Inc. announced FDA approval for its clinical study focusing on low-dose intravenous ketamine infusions for patients with Major Depression Disorder (MDD). The study, which involves 35 participants with inadequate responses to existing antidepressants, aims to analyze EEG changes during and after treatment. This marks a pivotal step in exploring ketamine's potential as a treatment for MDD, especially given the growing global prevalence of depression. Ehave seeks to address the limitations of current pharmacological options with its innovative approach.

Ehave, Inc. (OTC Pink: EHVVF) issued a shareholder letter detailing achievements in 2022 amid economic challenges, including inflation and rising interest rates. The company highlighted a $380 million triangular merger involving its subsidiary, Mycotopia Therapies, aimed at NASDAQ trading approval. Key milestones included the acquisition of Rejuv IV, now KetaDASH, which provides at-home ketamine treatments. Ehave also launched MetaHealthU, a platform for patient data integration, and MetaHealthYuru, an AI-driven mental health monitor. The company plans to expand its subsidiaries in 2023.

Ehave, Inc. (OTC Pink: EHVVF) announced that its KetaDASH subsidiary will receive its KetaDASH Mobile Unit in Miami Beach, Florida, on June 10, 2022. This custom medical van will facilitate in-home Ketamine IV treatments, providing real-time health data to enhance clinical outcomes. KetaDASH has already begun operations in Sacramento and San Francisco, offering managed services to streamline physician practices and improve patient care. CEO Ben Kaplan emphasized ketamine's potential for treating various psychological conditions, showcasing the company's commitment to innovative healthcare solutions.

Ehave, Inc. (EHVVF) has announced that its subsidiary, KetaDASH, will utilize precision medicine in psychedelic-assisted therapy through a partnership with HaluGen Life Sciences. This collaboration will employ a genetic testing kit to assess patients' genetic profiles and risk factors. The aim is to personalize treatment based on individual genetic variations, particularly focusing on gene mutations that influence responses to ketamine and other psychedelics. This innovative approach positions KetaDASH as a pioneer in integrating genetics into psychedelic therapy, enhancing patient outcomes and differentiating the company in a competitive market.

Ehave, Inc. (OTC Pink: EHVVF) has disclosed its ownership of approximately 9,793,754 shares in Mycotopia Therapies, valued over $24 million. The company announced a triangular merger with Ei.Ventures, targeting completion by July 30, 2022. This merger aims to establish PSLY.COM, focusing on mental health solutions leveraging psychoactive compounds and technology. Ehave’s stake in Mycotopia is valued at over $0.10 per share, and the merger could potentially benefit shareholders by monetizing existing assets while integrating new opportunities in mental health therapy.

Ehave, Inc. (OTC Pink: EHVVF) has announced its mobile application platform, MetaHealthU, will focus on understanding and curing hallucinogen-persisting perception disorder (HPPD). Partnering with the University of Melbourne, Ehave aims to collect data and biomarkers for HPPD research. The app empowers users to manage their health data securely, leveraging blockchain technology for improved privacy and efficiency. A pilot study for HPPD is set to begin in mid-2022. Ehave aims to lead in mitigating negative side effects of psychedelic treatments by analyzing genetic predispositions related to HPPD.

Ehave, Inc. (OTC Pink: EHVVF) announced a partnership with Heally to enhance its KetaDASH platform. This collaboration will provide licensed psychotherapists and registered nurses for patients seeking alternative treatments like ketamine therapy. The KetaDASH service offers in-home psychedelic therapy sessions, connecting patients with professionals via Heally's telehealth portal. This move is seen as a response to rising mental health issues exacerbated by the COVID-19 pandemic, aiming to improve access to care and patient outcomes in the mental health sector.

Ehave, Inc. (OTC Pink: EHVVF) has licensed advanced AI technology from Vastmindz to enhance its MetaHealthU offerings. Set to monetize this technology in 2022, Ehave aims to integrate features in its Ehave Dashboard to monitor vital statistics such as Heart Rate and Oxygen Saturation through facial light absorption analysis. Vastmindz's CEO recently showcased their innovation on the Unicorn Hunters platform, a show with over 14.5 million viewers, receiving positive remarks from tech experts like Steve Wozniak. This partnership is positioned to broaden healthcare accessibility globally.

Ehave, Inc. (EHVVF) has launched KetaDASH, a managed service offering in-home ketamine therapy for patients with treatment-resistant mental health issues. The service starts in the San Francisco Bay Area and Greater Sacramento Area, with plans to expand. KetaDASH focuses on safety and patient comfort, featuring a team of qualified professionals providing treatments after an initial telemedicine consultation. This initiative aims to broaden access to ketamine therapy, which has shown promise in treating conditions like depression and PTSD, thereby enhancing patient outcomes.